Therefore, we posed whether the MFR regimen affects the FRA1 expression that correlates with differences in phenotype, radioresistance, migration behavior, and p53 status of MFR-surviving NSCLC cells. This evidence concerns the gene FOSL1 and non-small cell lung carcinoma.